
MRSN Valuation
Mersana Therapeutics Inc
- Overview
- Forecast
- Valuation
- Earnings
MRSN Relative Valuation
MRSN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, MRSN is overvalued; if below, it's undervalued.
Historical Valuation
Mersana Therapeutics Inc (MRSN) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.80 is considered Undervalued compared with the five-year average of -4.54. The fair price of Mersana Therapeutics Inc (MRSN) is between 9.46 to 34.75 according to relative valuation methord. Compared to the current price of 7.70 USD , Mersana Therapeutics Inc is Undervalued By 18.64%.
Relative Value
Fair Zone
9.46-34.75
Current Price:7.70
18.64%
Undervalued
-0.18
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
Mersana Therapeutics Inc. (MRSN) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -2.90. The thresholds are as follows: Strongly Undervalued below -10.21, Undervalued between -10.21 and -6.55, Fairly Valued between 0.76 and -6.55, Overvalued between 0.76 and 4.41, and Strongly Overvalued above 4.41. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.40
EV/EBIT
Mersana Therapeutics Inc. (MRSN) has a current EV/EBIT of 0.40. The 5-year average EV/EBIT is -2.83. The thresholds are as follows: Strongly Undervalued below -10.33, Undervalued between -10.33 and -6.58, Fairly Valued between 0.92 and -6.58, Overvalued between 0.92 and 4.66, and Strongly Overvalued above 4.66. The current Forward EV/EBIT of 0.40 falls within the Historic Trend Line -Fairly Valued range.
1.80
PS
Mersana Therapeutics Inc. (MRSN) has a current PS of 1.80. The 5-year average PS is 2244.33. The thresholds are as follows: Strongly Undervalued below -15431.30, Undervalued between -15431.30 and -6593.49, Fairly Valued between 11082.14 and -6593.49, Overvalued between 11082.14 and 19919.96, and Strongly Overvalued above 19919.96. The current Forward PS of 1.80 falls within the Historic Trend Line -Fairly Valued range.
-0.52
P/OCF
Mersana Therapeutics Inc. (MRSN) has a current P/OCF of -0.52. The 5-year average P/OCF is -5.39. The thresholds are as follows: Strongly Undervalued below -14.67, Undervalued between -14.67 and -10.03, Fairly Valued between -0.75 and -10.03, Overvalued between -0.75 and 3.89, and Strongly Overvalued above 3.89. The current Forward P/OCF of -0.52 falls within the Overvalued range.
-0.53
P/FCF
Mersana Therapeutics Inc. (MRSN) has a current P/FCF of -0.53. The 5-year average P/FCF is -5.48. The thresholds are as follows: Strongly Undervalued below -14.31, Undervalued between -14.31 and -9.90, Fairly Valued between -1.07 and -9.90, Overvalued between -1.07 and 3.35, and Strongly Overvalued above 3.35. The current Forward P/FCF of -0.53 falls within the Overvalued range.
Mersana Therapeutics Inc (MRSN) has a current Price-to-Book (P/B) ratio of -1.24. Compared to its 3-year average P/B ratio of 24.00 , the current P/B ratio is approximately -105.18% higher. Relative to its 5-year average P/B ratio of 16.01, the current P/B ratio is about -107.77% higher. Mersana Therapeutics Inc (MRSN) has a Forward Free Cash Flow (FCF) yield of approximately -196.82%. Compared to its 3-year average FCF yield of -62.27%, the current FCF yield is approximately 216.07% lower. Relative to its 5-year average FCF yield of -43.93% , the current FCF yield is about 348.01% lower.
-1.24
P/B
Median3y
24.00
Median5y
16.01
-196.82
FCF Yield
Median3y
-62.27
Median5y
-43.93
Competitors Valuation Multiple
The average P/S ratio for MRSN's competitors is 3.81, providing a benchmark for relative valuation. Mersana Therapeutics Inc Corp (MRSN) exhibits a P/S ratio of 1.80, which is -52.65% above the industry average. Given its robust revenue growth of -70.21%, this premium appears unsustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of MRSN decreased by 84.60% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -208.83 to -875.93.
The secondary factor is the Revenue Growth, contributed -70.21%to the performance.
Overall, the performance of MRSN in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch

OPTX
Syntec Optics Holdings Inc
2.100
USD
+4.90%

HYPR
Hyperfine Inc
1.100
USD
+1.85%

FUSB
First US Bancshares Inc
13.150
USD
+0.23%

VANI
Vivani Medical Inc
1.600
USD
-0.62%

CLSD
Clearside Biomedical Inc
0.445
USD
-10.46%

PMVP
PMV Pharmaceuticals Inc
1.510
USD
+7.09%

NSPR
InspireMD Inc
2.440
USD
+0.41%

BNR
Burning Rock Biotech Ltd
6.900
USD
+1.47%

LSF
Laird Superfood Inc
7.060
USD
-4.59%
FAQ

Is Mersana Therapeutics Inc (MRSN) currently overvalued or undervalued?
Mersana Therapeutics Inc (MRSN) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.80 is considered Undervalued compared with the five-year average of -4.54. The fair price of Mersana Therapeutics Inc (MRSN) is between 9.46 to 34.75 according to relative valuation methord. Compared to the current price of 7.70 USD , Mersana Therapeutics Inc is Undervalued By 18.64% .

What is Mersana Therapeutics Inc (MRSN) fair value?

How does MRSN's valuation metrics compare to the industry average?

What is the current P/B ratio for Mersana Therapeutics Inc (MRSN) as of Jul 28 2025?

What is the current FCF Yield for Mersana Therapeutics Inc (MRSN) as of Jul 28 2025?

What is the current Forward P/E ratio for Mersana Therapeutics Inc (MRSN) as of Jul 28 2025?
